ChemicalBook > CAS DataBase List > Satralizumab
Satralizumab
- Product Name
- Satralizumab
- CAS No.
- 1535963-91-7
- Chemical Name
- Satralizumab
- Synonyms
- Research Grade Satralizumab;Research Grade Satralizumab(DHC36904)
- CBNumber
- CB68080965
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Satralizumab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Satralizumab Chemical Properties,Usage,Production
Uses
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Satralizumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Satralizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 15002134094
- marketing@targetmol.cn
- Country
- China
- ProdList
- 29358
- Advantage
- 58
1535963-91-7, SatralizumabRelated Search:
Tilvestamab
Pivekimab
Durvalumab
Lebrikizumab
Carlumab
Anvatabart
Aducanumab
catumaxomab
Enibarcimab
Naxitamab